Oslo, Norway, September 22, 2021 - Lytix Biopharma, a Norwegian immune-oncology
company, today announce that the US Patent Office has granted two patents in the
US and covering the use of its leading product candidate LTX-315 in combination
with chemotherapeutic agents US (11123398) and with the checkpoint inhibitor
anti-CTLA-4 (US 11083774).

"We are very satisfied with the success of our patent prosecution related to our
patent families in the US, the most important market world-wide for
pharmaceutical products. These grants highlight the novelty of our therapy and
further strengthens our business case as securing intellectual property rights
is of critical importance for the protection of Lytix' technology platform and
the long-term value generation of the company," says Dr. Øystein Rekdal, CEO of
Lytix Biopharma.

In July 2021, Lytix Biopharma announced the official opening of a Phase II
combination study in the US with LTX-315 and the immune checkpoint inhibitor
Pembrolizumab, which blocks tumor cells' ability to inhibit the body's immune
response, in patients with solid tumors. Results from earlier-initial studies
indicate that the combination of LTX-315 and Pembrolizumab may work better than
Pembrolizumab alone. The trial will be a multicenter study including MD Anderson
Cancer Center in Texas, which is one of the world leading cancer hospitals.  

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358, 
E-mail: Oystein.Rekdal@lytixbiopharma.com 

About Lytix Biopharma 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic peptide that has
demonstrated superior abilities to induce polyclonal T cell responses.